Noubar Afeyan's Moderna expects its COVID-19 vaccine to protect against UK coronavirus variant
Moderna Inc said on Wednesday it expects that the immunity induced by its COVID-19 vaccine would be protective against the coronavirus variants reported in the UK, Reuters reported.
The company, co-founded and headed by American entrepreneur of Armenian descent Noubar Afeyan, said it plans to run tests to confirm the vaccine’s activity against any strain.
Moderna’s comments came amid the British government’s plan to place huge swathes of England under its strictest COVID-19 restrictions as a highly infectious virus variant sweeps the country.
The company said it expects its vaccine, which was recently granted the U.S. emergency use authorization, to be protective against the UK variant based on data to date.
"We have already tested sera from animals and humans vaccinated with the Moderna COVID-19 Vaccine against a number of previous variants of the SARS-CoV-2 virus that have emerged since the first outbreak of the pandemic and found our vaccine to remain equally effective," Moderna said. (bit.ly/3pi3kqi)
The U.S.-based company said it would be performing additional tests of the vaccine in the coming weeks to confirm its expectation.
Related news
- Anthony Fauci receives Moderna vaccine, has 'extreme confidence' it's safe, effective
- US approves Moderna as second Covid-19 vaccine
- Moderna ditches 400,000 Covid-19 vaccine doses
- Moderna says its vaccine is 94.5% effective in preventing COVID-19